Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use; Draft Guidance for Industry and Food and Drug Administration Staff; Extension of Comment Period

Özet

The Food and Drug Administration (FDA) is extending to May 7, 2014, the comment period for the notice that appeared in the Federal Register of January 7, 2014 (79 FR 830). In the notice, FDA requested comments on a draft guidance document entitled "Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use." The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.